ProtoKinetix, Incorporated (PKTX)
USD 0.01
(-16.79%)
USD 0.01
(-16.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -20.4 Thousand USD | 20.13% |
| 2022 | -25.55 Thousand USD | 55.62% |
| 2021 | -57.56 Thousand USD | 70.24% |
| 2020 | -193.44 Thousand USD | 48.74% |
| 2019 | -377.34 Thousand USD | -177.4% |
| 2018 | -136.02 Thousand USD | 26.58% |
| 2017 | -185.28 Thousand USD | 50.06% |
| 2016 | -371.02 Thousand USD | 0.01% |
| 2015 | -371.07 Thousand USD | -327.75% |
| 2014 | 162.93 Thousand USD | -63.03% |
| 2013 | 440.76 Thousand USD | 32.72% |
| 2012 | 332.09 Thousand USD | -0.04% |
| 2011 | 332.22 Thousand USD | 16.33% |
| 2010 | 285.58 Thousand USD | -23.73% |
| 2009 | 374.46 Thousand USD | 24.29% |
| 2008 | 301.28 Thousand USD | 14.71% |
| 2007 | 262.65 Thousand USD | 258.11% |
| 2006 | -166.11 Thousand USD | -720.94% |
| 2005 | 26.75 Thousand USD | -14.92% |
| 2004 | 31.44 Thousand USD | 30334.62% |
| 2003 | -104.00 USD | 82.04% |
| 2002 | -579.00 USD | 83.52% |
| 2001 | -3513.00 USD | 31.98% |
| 2000 | -5165.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2836.00 USD | 86.1% |
| 2024 Q2 | -2200.00 USD | 22.43% |
| 2023 Q1 | -6942.00 USD | 72.83% |
| 2023 Q2 | -18.65 Thousand USD | -168.73% |
| 2023 FY | -20.4 Thousand USD | 20.13% |
| 2023 Q3 | -12.39 Thousand USD | 33.55% |
| 2023 Q4 | -20.4 Thousand USD | -64.63% |
| 2022 Q2 | -18.83 Thousand USD | 68.02% |
| 2022 FY | -25.55 Thousand USD | 55.62% |
| 2022 Q1 | -58.87 Thousand USD | -2.28% |
| 2022 Q3 | -43.71 Thousand USD | -132.14% |
| 2022 Q4 | -25.55 Thousand USD | 41.55% |
| 2021 FY | -57.56 Thousand USD | 70.24% |
| 2021 Q3 | -145.29 Thousand USD | -71.76% |
| 2021 Q4 | -57.56 Thousand USD | 60.38% |
| 2021 Q1 | -250.36 Thousand USD | -29.43% |
| 2021 Q2 | -84.59 Thousand USD | 66.21% |
| 2020 FY | -193.44 Thousand USD | 48.74% |
| 2020 Q3 | -44.76 Thousand USD | 1.21% |
| 2020 Q4 | -193.44 Thousand USD | -332.15% |
| 2020 Q2 | -45.3 Thousand USD | 5.39% |
| 2020 Q1 | -47.88 Thousand USD | 87.31% |
| 2019 Q4 | -377.34 Thousand USD | -30.18% |
| 2019 Q3 | -289.85 Thousand USD | 42.46% |
| 2019 Q1 | -24.1 Thousand USD | 82.28% |
| 2019 FY | -377.34 Thousand USD | -177.4% |
| 2019 Q2 | -503.78 Thousand USD | -1989.7% |
| 2018 Q2 | -214.4 Thousand USD | -11.59% |
| 2018 Q1 | -192.14 Thousand USD | -3.7% |
| 2018 FY | -136.02 Thousand USD | 26.58% |
| 2018 Q4 | -136.02 Thousand USD | -23.11% |
| 2018 Q3 | -110.49 Thousand USD | 48.46% |
| 2017 Q4 | -185.28 Thousand USD | 52.02% |
| 2017 FY | -185.28 Thousand USD | 50.06% |
| 2017 Q3 | -386.14 Thousand USD | -62.06% |
| 2017 Q2 | -238.27 Thousand USD | 56.61% |
| 2017 Q1 | -549.18 Thousand USD | -48.02% |
| 2016 Q3 | -88.96 Thousand USD | 18.01% |
| 2016 Q1 | -260.97 Thousand USD | 29.67% |
| 2016 FY | -371.02 Thousand USD | 0.01% |
| 2016 Q4 | -371.02 Thousand USD | -317.05% |
| 2016 Q2 | -108.51 Thousand USD | 58.42% |
| 2015 Q4 | -371.07 Thousand USD | -126.92% |
| 2015 Q3 | -163.52 Thousand USD | -1035.44% |
| 2015 Q2 | -14.4 Thousand USD | 53.01% |
| 2015 Q1 | -30.65 Thousand USD | -118.81% |
| 2015 FY | -371.07 Thousand USD | -327.75% |
| 2014 Q1 | 419.2 Thousand USD | -4.89% |
| 2014 FY | 162.93 Thousand USD | -63.03% |
| 2014 Q4 | 162.93 Thousand USD | -66.36% |
| 2014 Q3 | 484.39 Thousand USD | 13.91% |
| 2014 Q2 | 425.23 Thousand USD | 1.44% |
| 2013 Q3 | 405.97 Thousand USD | -0.62% |
| 2013 Q2 | 408.5 Thousand USD | -0.62% |
| 2013 Q1 | 411.05 Thousand USD | 23.78% |
| 2013 FY | 440.76 Thousand USD | 32.72% |
| 2013 Q4 | 440.76 Thousand USD | 8.57% |
| 2012 Q2 | 331.97 Thousand USD | -5.59% |
| 2012 Q3 | 311.88 Thousand USD | -6.05% |
| 2012 FY | 332.09 Thousand USD | -0.04% |
| 2012 Q4 | 332.09 Thousand USD | 6.48% |
| 2012 Q1 | 351.62 Thousand USD | 5.84% |
| 2011 FY | 332.22 Thousand USD | 16.33% |
| 2011 Q4 | 332.22 Thousand USD | 6.34% |
| 2011 Q3 | 312.41 Thousand USD | 204.12% |
| 2011 Q2 | 102.73 Thousand USD | 401.56% |
| 2011 Q1 | 20.48 Thousand USD | -92.83% |
| 2010 Q1 | 347.33 Thousand USD | -7.24% |
| 2010 FY | 285.58 Thousand USD | -23.73% |
| 2010 Q4 | 285.58 Thousand USD | -2.9% |
| 2010 Q3 | 294.11 Thousand USD | -12.36% |
| 2010 Q2 | 335.6 Thousand USD | -3.38% |
| 2009 Q4 | 374.46 Thousand USD | 0.82% |
| 2009 Q2 | 363.12 Thousand USD | 9.05% |
| 2009 Q1 | 332.99 Thousand USD | 10.53% |
| 2009 FY | 374.46 Thousand USD | 24.29% |
| 2009 Q3 | 371.41 Thousand USD | 2.28% |
| 2008 FY | 301.28 Thousand USD | 14.71% |
| 2008 Q4 | 301.28 Thousand USD | 14.79% |
| 2008 Q3 | 262.46 Thousand USD | 18.11% |
| 2008 Q2 | 222.21 Thousand USD | 147.41% |
| 2008 Q1 | 89.81 Thousand USD | -65.8% |
| 2007 FY | 262.65 Thousand USD | 258.11% |
| 2007 Q3 | 229.75 Thousand USD | 430.02% |
| 2007 Q4 | 262.65 Thousand USD | 14.32% |
| 2007 Q2 | -69.61 Thousand USD | 44.82% |
| 2007 Q1 | -126.16 Thousand USD | 24.05% |
| 2006 FY | -166.11 Thousand USD | -720.94% |
| 2006 Q2 | -342.89 Thousand USD | -4.58% |
| 2006 Q3 | -268.49 Thousand USD | 21.7% |
| 2006 Q4 | -166.11 Thousand USD | 38.13% |
| 2006 Q1 | -327.88 Thousand USD | -1325.64% |
| 2005 Q3 | -35.34 Thousand USD | 82.99% |
| 2005 FY | 26.75 Thousand USD | -14.92% |
| 2005 Q4 | 26.75 Thousand USD | 175.7% |
| 2005 Q2 | -207.81 Thousand USD | -87.59% |
| 2005 Q1 | -110.77 Thousand USD | -452.31% |
| 2004 Q3 | 275.84 Thousand USD | 3.95% |
| 2004 Q1 | 101.84 Thousand USD | 98024.04% |
| 2004 Q2 | 265.35 Thousand USD | 160.56% |
| 2004 Q4 | 31.44 Thousand USD | -88.6% |
| 2004 FY | 31.44 Thousand USD | 30334.62% |
| 2003 Q4 | -104.00 USD | 84.22% |
| 2003 Q3 | -659.00 USD | 0.0% |
| 2003 FY | -104.00 USD | 82.04% |
| 2003 Q2 | -659.00 USD | 0.0% |
| 2002 FY | -579.00 USD | 83.52% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | -3513.00 USD | 31.98% |
| 2000 FY | -5165.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -1457.863% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.361% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.048% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 91.824% |
| Rebus Holdings, Inc. | 305 Thousand USD | 106.691% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 99.676% |
| Qrons Inc. | 351.42 Thousand USD | 105.807% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 103.279% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.047% |
| Skye Bioscience, Inc. | -5.72 Million USD | 99.643% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.129% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.496% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 105.079% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.944% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.91% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 102.201% |
| Mesoblast Limited | 55.85 Million USD | 100.037% |
| Marizyme, Inc. | 18.56 Million USD | 100.11% |
| Genus plc | 190.6 Million USD | 100.011% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.913% |
| Pharming Group N.V. | 109.8 Million USD | 100.019% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 102.372% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 101.681% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 103.001% |
| ContraFect Corporation | -6.02 Million USD | 99.661% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 115.158% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 101.766% |
| IMV Inc. | 7.67 Million USD | 100.266% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.371% |
| MultiCell Technologies, Inc. | 90.04 USD | 22765.482% |
| ONE Bio Corp. | 9.04 Million USD | 100.226% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 97.22% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.158% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 101.492% |
| Q BioMed Inc. | 4.06 Million USD | 100.503% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.067% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 102.025% |
| Biomind Labs Inc. | 711.4 Thousand USD | 102.869% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.034% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 101.021% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.159% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 105.673% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 114.598% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 202.723% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.927% |
| GB Sciences, Inc. | 1.74 Million USD | 101.168% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 88.896% |
| HST Global, Inc. | 96.79 Thousand USD | 121.084% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 109.896% |
| Halberd Corporation | 144.72 Thousand USD | 114.102% |
| Enzolytics Inc. | 981.65 Thousand USD | 102.079% |
| Agentix Corp. | 37.63 Thousand USD | 154.232% |
| Resverlogix Corp. | 6.45 Million USD | 100.316% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 96.968% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.999% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.957% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.289% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.753% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 99.769% |
| AVAX Technologies, Inc. | -5.9 Million USD | 99.654% |
| Zenith Capital Corp. | 10.06 Thousand USD | 302.782% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 110.182% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.855% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 112.405% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -11.41% |
| Kadimastem Ltd | -253.1 Thousand USD | 91.937% |
| Helix BioMedix, Inc. | -2.57 Million USD | 99.206% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.101% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.456% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 110.14% |
| LadRx Corporation | -2.03 Million USD | 98.998% |
| Cell Source, Inc. | 9.23 Million USD | 100.221% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 103.213% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 103.213% |
| NovAccess Global Inc. | 2.17 Million USD | 100.937% |
| Affymax, Inc. | -5.59 Million USD | 99.635% |
| Itoco Inc. | 228.3 Thousand USD | 108.939% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 115.007% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.412% |
| Mobile Lads Corp. | 484.23 Thousand USD | 104.215% |
| CytoDyn Inc. | 20.26 Million USD | 100.101% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -3054.25% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -120.19% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.265% |
| SYBLEU INC | 473.71 Thousand USD | 104.308% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.458% |
| International Stem Cell Corporation | 2.59 Million USD | 100.788% |
| Bioxytran, Inc. | 1.89 Million USD | 101.075% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 132.698% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.936% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 100.594% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.239% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 102.641% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 98.367% |
| Neutra Corp. | 52.18 Thousand USD | 139.106% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 99.18% |
| PureTech Health plc | -167.19 Million USD | 99.988% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 91.667% |
| IXICO plc | -4.44 Million USD | 99.541% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.154% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.037% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 99.953% |